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Abstract
Purpose—The purpose of this study was to describe the informed consent and assent experience 
for oncology research from the perspective of the participants: adolescents, their parents, and their 
physician providers.
Design & Methods—This descriptive mixed-methods study included the pilot use of the 
Quality of Informed Consent Questionnaire (QuIC) with an adolescent population and semi-
structured interviews with adolescents, their parents, and their physician providers within 48–72 
hours of the informed consent and assent discussion for a pediatric oncology clinical trial and 
again 6–9 weeks later.
Results—Adolescents and their parents scored considerably lower on Part A of the QuIC than 
Part B indicating a lower level of objective understanding of key elements of informed consent and 
assent. Qualitative interviews highlight participants’ self-reported poor memory or recollection of 
key details of the informed consent and assent discussion paralleling the QuIC findings for 
objective understanding.
Conclusion—Findings from this pilot descriptive study suggest adolescents and their parents 
feel more informed than they actually are. This dichotomy of experience seems to have been 
mitigated by a strong sense of trust in and connection with their physician provider.
Practice Implications—Further exploration of adolescent and parent viewpoints regarding 
what they value as important in the content of the informed consent and assent and how that 
content is delivered is warranted. Additionally, understanding the origin of participants’ 
misunderstanding of the key elements of consent and assent may illuminate areas for future 
intervention-based research focused on improving the overall quality of informed consent and 
assent discussions.
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Informed Consent; Assent; Adolescent; Oncology Research
Involving children in decision making about participation in clinical research is mandated in 
this country by the Code of Federal Regulations (CFRs) and is manifest in the requirement 
to obtain informed assent from children prior to their participation in clinical research 
(Requirements for permission by parents or guardians and for assent by children, 1983). 
Despite a push to include children in clinical research (National Institutes of Health, 1998; 
Pediatric Research Equity Act, 2003; Best Pharmaceuticals for Children Act, 2002) and to 
involve them in decisions about their participation, research literature provides little 
exploration of the voice and perspective of the child in decision making processes, 
specifically informed consent and assent for oncology clinical trials (Stegenga et al., 2005). 
Previously, research examining children’s understanding of clinical research involvement 
and preference for participation (assent) has primarily utilized healthy children and 
hypothetical cases (Angst & Deatrick, 1996; Bradlyn, Kao, Beale, & Cole, 2004; Geller, 
Tambor, Bernhardt, Fraser, & Wissow, 2003; Kunin, 1997; Rossi, Reynolds, & Nelson, 
2003). While researchers have attempted to quantify the child’s level of participation in 
actual consent and assent discussions (Olechnowicz, Eder, Simon, Zyzanski, & Kodish, 
2002) and conceptually explore children’s competence to participate in research and 
treatment decision making (Miller, Drotar, & Kodish, 2004; Coyne, 2005), there are few data 
that directly address the child’s self-reported experience. Understanding the perspective of 
children and their parents involved in these discussions is paramount to research aimed at 
improving a less than ideal process in actual clinical practice (Hinds, 2009; Sugarman, 
1999).
Background
Ethicists and clinicians involved in human subjects research have been concerned with 
participants’ misperceptions of elements of the informed consent process for years. Clinical 
trial participants across the world have consistently shown a lack of comprehension of 
essential informed consent elements, most notably randomization and placebo design 
elements (Mandava, Pace, Campbell, Emanuel, & Grady, 2012). Challenges to describing 
key elements of consent and assent in actual clinical research practice have led to a number 
of investigative studies (Burman, Breese, Weis, Bock, Bernardo, Vernon, 2003; Resnik, 
Peddada, Atilio, Wang, & Menikoff, 2008; Johnson et al., 2015). While much empirical 
research literature on informed consent has focused on poor understanding and created and 
tested interventions to improve the overall quality of informed consent, success at improving 
understanding of the key elements of informed consent has been very limited (Flory & 
Emanuel, 2004).
In the context of pediatric oncology research, clinical trial involvement is high and accounts 
for substantial improvement in survival rates, with the 5 year relative survival rate up from 
58% for children diagnosed between 1975–1977 to 83% for children diagnosed between 
2004–2010 (Seigel, Miller, & Jemal, 2015). Approximately 4,000 children diagnosed with 
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cancer enroll in a Children’s Oncology Group sponsored clinical trial each year making this 
population a primary focus for informed consent and assent research (National Cancer 
Institute, 2014). Findings suggest adolescents may feel pressure from the clinical research 
team and their parents to enroll in clinical trials (Grady et al, 2014). Contrasting findings 
from adolescents in Phase I clinical trials suggest that the majority understand the concept of 
voluntariness and see themselves as the final decision-maker (Miller et al., 2013). 
Understanding how and why parents and adolescents make decisions about clinical trial 
participation is key in oncology research. Research indicates that factors influencing family 
decision making in clinical trials include: child characteristics such as health and 
developmental status, parent-child relationship, context of the research, and investigator 
characteristics (Broome, Kodish, Geller & Siminoff, 2003). Navigating key factors 
influencing family decision making in informed consent and assent, especially in oncology, 
requires involvement of key stakeholders in the discussion to include providers. Physicians 
in pediatric oncology report little previous formal training in facilitating informed consent 
and assent discussions, instead relying on modeling their mentors and attending physicians 
in the absence of a formal institutional protocol for consent processes (Kodish, Pentz, Noll, 
Ruccione, Buckley & Lange, 1998). Identifying content of these informed consent 
discussions can illuminate directions for further study. Dialogue in most informed consent 
conferences in pediatric oncology is devoted to the discussion of disease and treatment 
issues, with little time devoted to study discussion, risks/benefits and voluntariness of 
clinical trial participation (Olechnowicz et al., 2002).
Oncology patients have shown poor understanding of the design and purpose of clinical 
trials (Daugherty et al., 1995). Research with adults focused on the quality of the informed 
consent process utilizing the Quality of Informed Consent Questionnaire (QuIC) showed the 
majority of oncology patients were satisfied with the consent process yet had little 
understanding of key elements of the process outlined in the Code of Federal Regulations 
(General requirements for informed consent, 2005; Joffe et al., 2001). Similar results using 
the QuIC with adult participants demonstrated little understanding of concepts of clinical 
trial participation related to it not being standard treatment, having additional risk when 
compared to standard treatment, and the protocol being unproven (Barrett, 2005; Bergenmar, 
Molin, Wilking, and Brandbery, 2008). Pediatric oncology patients of the age of assent (>7 
years) involved in oncology clinical research similarly voiced poor understanding or 
recollection that their treatment was considered research, outlined little or no role in 
deciding to enroll in their trial, and expressed a feeling of being unable to dissent to trial 
enrollment (Ungaro, Sill, & Kamani, 2010).
Understanding the perspectives of participants can aid research aimed at improving the 
overall process from the perspective of the participants. Clarifying whether and how the 
federal regulations that guide this discussion are being operationalized and perceived by the 
participants in clinical research is a key next step to moving this area of research forward. 
The primary purpose of this descriptive mixed-methods study was to describe the informed 
consent and assent experience from the perspective of the participants: adolescents, their 
parents, and the physician providers participating in discussions for oncology clinical trials.
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This was a descriptive, longitudinal, mixed-methods research study with a heavily weighted 
qualitative approach. Concurrent qualitative (semi-structured interviews with adolescents, 
their parents/guardians, and their physician provider) and quantitative data collection (QuIC 
completed by adolescents and their parents/guardians) was utilized to form a baseline 
description of participants experiences of informed consent and assent. A longitudinal look 
at the informed consent and assent experiences for adolescents and their parents took place 
6–9 weeks after their initial informed consent and assent discussion (ICD/IAD).
Study Procedures
Study approval was obtained from the local Institutional Review Boards prior to subject 
enrollment. Potential research participants were identified by the clinical staff in the 
pediatric oncology clinics. Eligible research participants consented/assented to participate in 
this research study within 48–72 hours of the formal informed consent and assent discussion 
for the cancer clinical research trial. In Step 1, adolescents and their parents/guardians 
participated in either separate or joint audio-recorded qualitative interviews lasting 
approximately one hour. Adolescents and their parents/guardians were asked to provide a 
narrative of their informed consent and assent discussion experience (see Table 1 for sample 
interview structure). After the completion of the qualitative interviews, the parent/guardian 
and adolescent subjects completed short demographic forms and the study instrument 
(QuIC). The researcher completed a short descriptive form that captured relevant elements 
such as the clinical diagnosis of the adolescent participants. A member of the research staff 
that participated in the informed consent and assent process for the cancer clinical trial also 
participated in an audio-recorded qualitative interview with the researcher at this initial time 
point. A second qualitative interview was conducted with adolescents and their parents/
guardians approximately six to nine weeks after the completion of the induction phase for 
the cancer clinical trial.
Sample and Setting
Data were collected from a convenience sample of adolescent patients, their parents/
guardians, and their physician providers at two separate pediatric oncology clinics in 
academic medical centers located in the Mid-Atlantic United States. Specific eligibility 
criteria for adolescent participants included 1) being age 12 to <18 years at time of study 
entry with a new diagnosis of cancer; 2) completed informed assent discussion for Phase II-
III pediatric oncology research trial; and 3) ability to understand written and spoken English. 
Exclusion criterion for adolescents and their parents included any cognitive deficit that 
would have made either of them eligible for a waiver of consent or assent for the cancer 
clinical research trial based on physician investigator judgment. Specific eligibility criteria 
for parent/guardian participants included 1) parental status (biological or legal guardian) of 
an adolescent who participated in the informed consent and assent discussion for a Phase II-
III pediatric oncology clinical research trial, and 2) ability to understand written and spoken 
English. The physician provider/physician investigator who facilitated the ICD/IAD for the 
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oncology clinical trial for the adolescent and parent/guardian dyads was approached for 
participation. There were no exclusion criteria for providers.
Quantitative Measure: QuIC
The QuIC questionnaire developed by Joffe, Cook, Cleary, Clark, and Weeks (2001) 
measures actual (objective) and perceived (subjective) understanding of the informed 
consent process. Eight relevant domains for measurement of the quality of informed consent 
were derived from federal regulations outlined in the Code of Federal Regulations (General 
requirements for informed consent, 2005). Part A measures objective understanding with 
item responses ranging from disagree (1), unsure (2), or agree (3) to statements such as “The 
main reason cancer clinical trials are done is to improve the treatment of future cancer 
patients” (Joffe et al., 2001, A2). Part B measures subjective understanding, or perception of 
understanding, with item responses ranging from “I didn’t understand this at all” (1), to “I 
understood this very well” (5), to statements such as “I understand the possible risks and 
discomforts of participating in a clinical trial” (Joffe et al., 2001, B6). With a summary score 
range of 0–100, higher scores on Part A (a criterion-referenced measure) indicated a higher 
level of understanding of clinical trials or objective knowledge. With a summary score range 
of 0–100, scores on Part B (a norm-referenced measure) indicated a higher level of 
perception of understanding of clinical trials or subjective knowledge. Face and content 
validity of the QuIC were established via two independent expert panel reviews with experts 
in statistics, oncology, clinical trial design and bioethics. Test-retest reliability was 
established with intraclass coefficients (ICC) of .66 on Part A (objective understanding) 
and .77 on Part B (subjective understanding) (Joffe, et al, 2001).
Feasibility (to include evaluation of acceptability and timing) of QuIC use with adolescent 
participants occurred in this study via adolescent verbal reports following completion of the 
instrument. The brevity and readability level supported ease of adaptation of the instrument 
for an adolescent sample. Estimated time for completion was seven minutes.
Qualitative Measure: Semi-Structured Interviews
Adolescents, their parents/guardians, and a member of the clinical research staff participated 
in separate or joint audio-recorded qualitative interviews about their informed consent and 
assent experience lasting approximately one hour within 72 hours of the initial ICD/IAD for 
the oncology clinical trial. Adolescents, their parents/guardians, and physician providers 
were asked to tell the story of their informed consent and assent experience. Adolescents and 
their parents also participated in additional interviews 6–9 weeks later to reflect on what 
they remembered about the ICD/IAD.
Analysis Techniques
Qualitative and quantitative data were collected concurrently during Step 1 of the study, 
analyzed separately, and then examined for areas of convergence and difference in the 
interpretation phase. Transcripts of the qualitative interviews were analyzed using the 
following steps: data immersion, data transformation or reduction for relevant content, 
identification of strips, grouping of similar strips, identification of groups of strips into 
themes, and finally thematic analysis (Cohen, Kahn, & Steeves, 2000). Trustworthiness was 
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addressed by multiple design and analysis strategies. The researcher kept a reflective journal 
with field notes completed at the end of each interview in an attempt to enhance self-
awareness and credibility (Guba & Lincoln, 1989). Member checks were completed with 
each participant throughout their interviews to ensure authentic reports of their experiences 
(Guba & Lincoln, 1985). An audit trail was maintained throughout the data analysis phase to 
ensure ease of access to evaluate coding choices and definitions for larger categories and 
themes, enhancing dependability of the study (Guba & Lincoln, 1985).
Important themes and key elements of the ICD/IAD from the participants’ standpoint as 
highlighted during qualitative interviews were compared to participants’ scores on the QuIC 
to highlight similarities and differences. The QuIC, demographic data, and chart abstraction 
data were the secondary forms of data providing supportive explication of the qualitative 
data collected in participant interviews, thus a heavily weighted qualitative approach. 
Comparison of qualitative data (interviews), quantitative data (QuIC), demographic data, and 
chart data occurred side by side in the data interpretation phase of the study and is explored 
in the discussion of results.
Results
Participant Characteristics
The sample included 4 participant triads (adolescent, parent, clinician). Demographic 
information is summarized in Tables 2 & 3.
QuIC Results
In this study, the adolescents and their parents scored 72 or lower on a scale of 100 on Part 
A, indicating a low level of objective understanding of the essential elements of the informed 
consent and assent (see Table 4 for summary scores). Mean summary score for adolescents 
on Part A of the QuIC was 64.25 (SD 5.6) with a range of 53–72. Mean summary score for 
parents was 59.0 (SD 9.5) with a range of 47–70. Three out of four adolescents’ summary 
scores of 82 or higher for Part B, indicating they subjectively felt well informed. All four 
parents felt well informed with summary scores of 86 or higher for Part B. Mean summary 
score for adolescents on Part B of the QuIC was 79.25 (SD 9.6) with a range of 60–89. 
Mean summary score for parents on Part B was 93.0 (SD 7.0) with a range of 86–100.
Initial Interview Themes
Analysis of the transcriptions from interviews with adolescents, their parents and physician 
providers revealed seven key themes: Altruism, Overwhelmed, Fear and Lack of Control, 
Physician Provider Communication, Timeline and the Rush, the Protocol Roadmap, and 
Poor Memory (see Table 5 for definitions of themes and key examples of participant quotes 
demonstrating theme).
Altruism—Adolescent and parents highlighted their desire to give back as a motive for 
clinical trial participation. This was clearly a source of pride as they volunteered why they 
decided to participate in the cancer clinical trial. Adolescents described their desire to help 
others in a similar situation with reference to an idea of solidarity among those who have a 
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new oncology diagnosis and are new to clinical trials. Mothers spoke of their own family’s 
strengths and pride in their adolescent for “giving something back” when they spoke about 
their altruistic motives for participating in a clinical trial. Physician providers highlighted the 
purpose of the trial as “gathering data for the future (patients) of the world” which 
adolescents and parents translated as a motive for participation.
Overwhelmed—As adolescents and their mothers settled into the narrative descriptions of 
the informed consent and assent discussions they often began with a description of how they 
felt like they were being inundated with a large amount of information to include a new 
oncology diagnosis and subsequent complex informed consent and assent discussion that 
involved complex concepts and words. Adolescents and parents highlighted the complex, 
medically sophisticated language involved in oncology clinical trial discussions. Adolescents 
often referenced what they called “big word” or “giant words” used by the physician 
providers as an example of where they often became “lost” in the informed consent 
discussion.
Fear and Lack of Control—Adolescents and parents often expressed trepidation and lack 
of ability to manage a new oncology diagnosis and subsequent treatment options and 
decisions including the possibility of clinical trial participation. Adolescents were often 
hesitant to admit fear in the presence of their parents but often alluded to it as they discussed 
the future beyond their initial enrollment in the clinical trial. Mother’s expressed clear 
feelings of panic and lack of control as they faced the unknown with their child. Mother’s 
often did not express this fear in front of their child and elaborated that this was a defense to 
shield their child from what they perceived as a weakness in the face of a new oncology 
diagnosis and clinical trial participation. Physician providers did not provide any discussion 
related to observations of fear or lack of control on their part or from the perspective of the 
family within the context of the ICD/IAD.
Physician Provider Communication—Adolescents and mothers identified key 
characteristics of physician provider interactions and behaviors that influenced their positive 
perception of the consent and assent experience. They often highlighted how well their 
physician provider’s characteristics and habits of communication matched their own 
preference for receiving difficulty information in such a complex experience. One adolescent 
liked his physician provider and the “fact that he didn’t jump around the bush, and he told 
me straight forward.” Parents also noted their satisfaction with physician providers who 
demonstrated commitment to their child as an individual and utilized positive 
communication techniques that made them feel like they were “part of the conversation”, 
highlighting a patient centered approach. Mothers highlighted their satisfaction with their 
physician provider’s use of “layman terms” as a way to make complex medical concepts and 
terms more understandable. Similarly physician providers pointed to their strategy to utilize 
“layman terms” in an attempt to help adolescents and parents make sense of the complex 
medical content within their own context of experience. Descriptions from physician 
providers often began with details related to the consent and assent environment, describing 
the landscape of consent and assent in an attempt to illustrate establishing a connection with 
patients and their families. For one physician provider it was especially important to 
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illustrate the implied relationships between physician provider, patient, parent, and nurse by 
outlining where everyone was sitting for this discussion. The fact that all were on generally 
the same eye level for the discussion was both literally and metaphorically important for this 
physician provider to highlight an attempt to establish a connection with the patient and the 
patient’s family. The positions of those involved in the discussion were outlined to 
demonstrate a symbolic equal footing as they began this important discussion, therefore, 
eliminating any physical signs of power differentials.
Timeline and the Rush—Adolescents, mothers and physician providers all expressed a 
frustration with the quickened and pressured pace necessary to make decisions and 
implement a plan for treatment and clinical trial participation so soon after a new oncology 
diagnosis. This left adolescents feeling they did not have enough time to process all that was 
happening. Parents wished physician providers took more time during these discussions. 
Physician providers also expressed conflict between wanting to move quickly to provide 
their patient with the best possible outcome and wanting to take more time to go over key 
information.
Roadmap—Parents and adolescents outlined the necessary steps in the process for 
oncology clinical trial participation to include calendars, medications, procedures, and other 
trial specific time points. They were able to organize their thoughts about the consent and 
assent experience around what they called the roadmap or the visual interpretation of their 
treatment protocol and the different paths they could take. Understanding their treatment 
protocol and the order of activities in their new cancer dominated lives was important to 
adolescents and parents. The roadmap provided the structure to help them understand and 
move through this process. The roadmap stemmed from the physician provider’s 
presentation of what they call the necessary “schema” of how the clinical trial protocols 
work. Essential elements of the consent and assent discussion for physician providers 
centered on the actual roadmap for the protocol as dictated by the individual’s cancer 
clinical trial. The physician providers’ memories of the roadmap were more detailed than the 
memories that the mothers and adolescents provided.
Poor Memory—Parents and adolescents described an inability to remember specific 
content of the informed consent and assent discussions. They described their own poor 
memory about specific details about the ICD/IAD, specifically what was said and by whom. 
One mother felt she understood the discussion while it was happening, but once the 
discussion was over, her memory of what was actually said was sparse. Adolescents were 
open and nonchalant about their lack of specific memory related to consent and assent 
discussion details. When adolescents and parents attempted to recall specific content of the 
informed consent and assent forms, they often expressed frustration about what they could 
not remember. A sense of being overwhelmed and deluged with technical information in a 
foreign language (medical terminology) were often blamed for their “bad memory”. 
Physician provider comments did not highlight this particular theme.
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Themes from Follow-Up Interviews with Adolescents/Parents
During interviews 6–9 weeks after the initial ICD/IAD for their cancer clinical trial, 
adolescents and their mothers described what they remembered about the initial ICD/IAD. 
Both had a difficult time remembering key details about the content of the ICD/IAD, but 
were able to recall how they were feeling during that time and contrast it to their present day 
lives. Their feelings of fear and lack of control and general sense of being overwhelmed had 
waned as they saw themselves moving forward and achieving milestones within their 
individual protocols. Adolescents proudly recited details about the roadmap for their clinical 
trial and were precise in their descriptions of where they were on the roadmap. Adolescents 
and mothers spoke with greater confidence about their knowledge of drugs and treatments 
and expressed continued confidence in their physician providers. All continued to be 
satisfied with the ICD/IAD and attributed this to their confidence and positive connection 
with their physician provider.
Convergent and Divergent Findings: Integrating the Data
A comparison of findings from the semi-structured interviews and the QuIC highlights a 
dichotomy between how well adolescents and their parents felt the actual ICD/IAD went 
versus how much they actually understood key elements of informed consent and assent. 
Parents and adolescents showed a considerably higher level of subjective understanding than 
objective understanding of the essential informed consent and assent elements, meaning they 
perceived themselves more informed than they actually were. Both adolescents and parents 
scored low (<70%) in domains addressing individual understanding of foreseeable risks and 
discomforts as a result of clinical trial participation; potential benefits to self and others; 
available appropriate alternatives to clinical trial participation; different levels of 
confidentiality related to clinical trial participation; potential compensation for injury or 
illness related to clinical trial participation; and whom to contact with questions related to 
participation in a cancer clinical trial. In six out of eight domains of informed consent and 
assent outlined in the CFRs, participants averaged less than 70% in their overall scores 
related to understanding these elements. Seven out of eight adolescents and parents scored 
above 80% for subjective understanding of the key elements of informed consent and assent 
with no scores less than 50%. This provides an interesting contrast between participants’ 
actual or objective understanding and their subjective of the same elements of consent and 
assent. Adolescents and parent participants felt more informed than they actually were 
which parallels similar work in oncology consent research with adults who were generally 
satisfied with the informed consent experience but demonstrated less than clear 
understanding of key elements (Joffe et al., 2001).
QuIC findings for Part A indicated a low level of objective understanding of the essential 
elements of consent and assent that seems to match the participants’ description of “bad 
memory” or poor recollection of ICD/IAD details and lack of reference to the essential 
elements of the ICD/IAD in their narratives. The fact that both adolescents and parents 
described difficulty and frustration at not being able to recall details of the ICD/IAD 
parallels the low scores for objective understanding of the technical elements of the consent 
and assent discussion.
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However, “bad memory” or poor recollection of the actual details of the ICD/IAD seems to 
contrast their overall positive perception of the process and their physician provider. 
Physician providers that were straightforward and spoke in clear layman’s terms were 
appreciated and hailed as a positive part of the ICD/IAD. The ability for physician providers 
to match their delivery style and communication with the preferences and needs of 
adolescents and parents was considered part of the success of the overall ICD/IAD.
Divergent findings include the idea that when asked to describe their overall informed 
consent and assent experience, adolescents and parents focused on more subjective 
perceptions of the experience. Adolescents and parents moved beyond descriptions of the 
consent and assent environment, perhaps as a defense against their poor recollection of key 
concepts in the ICD/IAD. Instead, they focused on what went well during the discussion. 
This may indicate superficial misconception of understanding that was not identified by their 
physician provider during the actual ICD/IAD or an experience of being inundated with 
complex information and inability or lack of time to process clinical trial participation in the 
face of a new oncology diagnosis. As adolescents and mothers discussed memories of the 
consent and assent environment, they provided details about their providers that seemed to 
influence their experience of in a positive way. Physician providers who were forthcoming 
with adolescents and their families and used language they could understand, were 
appreciated. Physician providers who did not appear rushed were highlighted as good 
providers. Additionally, physician providers who helped families feel included in this 
decision-making process created strong connections that helped to establish a sense of trust 
and rapport.
Creating time and space between discussions related to diagnoses and discussions related to 
consent and assent was important to physician providers and families alike. Physician 
providers indicated that their preference was to spread out the discussions over several days 
to allow for adequate time for families to process the new information. Yet, they expressed 
frustration at the necessary rushed pace that must be kept to give adolescents their best 
chance at a positive outcome.
Some of the negative aspects of the ICD/IAD were related to the inability of adolescents and 
their mothers to recall all that they wanted to about the ICD/IADs. Adolescents and their 
mothers focused on their own functional memory as an important element of their ICD/IAD 
and described their memory as “bad”, sometimes expressing fear and concern related to 
what they could not remember about the discussion. This highlights the necessity of 
revisiting the elements of the ICD/IAD with patients and families throughout their 
participation in a clinical trial. The idea that consent and assent are ongoing processes is one 
well documented in clinical research ethics literature (Capron, 2008), yet the reality of 
clinical practice does not often reflect this in any formalized pattern.
Altruism seemed to motivate some of the adolescents’ and mothers’ participation decisions, 
allowing them to feel some level of pride in their decision to participate in a cancer clinical 
trial and, to some extent, softening the devastating news of a new cancer diagnosis. 
Adolescents and mothers expressed gratitude at being able to “tell their story” and wanted to 
share with future cancer patients the message that they are not alone.
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Participants’ descriptions of their individual roadmaps comprised an important component 
of how they remembered the ICD/IAD and illustrated what elements of that discussion 
seemed to stick out as important to remember. Although physician providers also 
highlighted the roadmap, mothers and adolescents seemed to hold onto the details of the 
roadmap in an effort to regain control in an overwhelming situation.
Discussion
Key Lessons
This study offers a triadic evaluation of informed consent and assent experiences as reported 
in near real time by adolescent, parent and physician provider. Study measures and initial 
interviews took place within 48–72 hours of the informed consent and assent discussion for 
the oncology clinical trial. A rare glimpse into what is happening in these discussions from 
the perspectives of the participants without the potential biasing effect of an informed 
consent researcher in the room observing the oncology clinical trial informed consent 
discussion provides a new lens for evaluating this complex experience.
Discrepancies between the QuIC results and perceptions articulated during interviews with 
adolescents, parents and physician providers demonstrate a conflict between participants 
feeling informed and actually being informed. Adolescents and their parents generally felt 
more informed than they actually were. Part B summary scores of the QuIC for both 
adolescents and their parents indicated higher subjective understanding of key elements of 
informed consent which parallels their excellent perceptions of the overall experience as 
described in their interviews and indicates that they felt informed. Contrasting results from 
Part A of the QuIC indicated that they were less informed than they felt were. While these 
findings do not diverge from the initial QuIC research completed by Joffe and colleagues 
(2001), they do provide a more nuanced background for interpreting the participant 
perceptions as articulated by adolescents and their parents in the interviews in this study. It is 
difficult to separate the experience of distress and uncertainty associated with a new 
oncology diagnosis and the experience of informed consent and assent in this population as 
these two complex experiences happen in nearly the same space and time and are often 
overlapping. Perhaps it is not a realistic expectation for adolescents and their parents to 
demonstrate clear understanding of the key elements of assent and consent process within 
the context of a new oncology diagnosis, yet the basic tenets of human subjects’ protection 
must be attended to with valid and meaningful informed consent and assent discussions. 
This presents real challenges for researchers and clinicians and reflects the complexity of 
this space in the journey for adolescents and their parents.
Limitations and Strengths
During the recruitment period there was a significant drop in the number of new oncology 
cases at the primary site as well as an unusually low number of open clinical trials for this 
particular age group when compared to the previous two years. A total of four eligible triads 
surfaced and all four eligible triads agreed to participate in this study. Although this 
represents a small sample size, the study generated a substantial amount of qualitative data 
for analysis with over 30 hours of interviews for analysis, indicating a high level of 
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engagement with participants and a significant interest from participants in ‘sharing their 
story’. This design included a retrospective look at the consent and assent experience. 
Retrospective descriptions of complex processes can sometimes create skewed 
representations of the actual process. In this study, the retrospective nature of the interview 
was a benefit, as participants had time to reflect on their assent experience and provide 
insights that may not have been available ‘in the moment’ or during their actual consent and 
assent experience. In addition, the QuIC was piloted with an adolescent sample for the first 
time in this study. Average time for completion of the QuIC was 10 minutes for adolescents 
and 12 minutes for parents. All adolescent and parent participants reported that the QuIC 
was “easy” to complete, although some parent felt that the questions seemed repetitive, as 
the language used in different questions seemed very similar. This questionnaire may be a 
feasible tool to use in this population but must be tested in a larger population to provide 
additional evidence for validity and reliability with this age group.
Conclusions
Implications for Future Research
The original developers of the QuIC indicated that adequate disclosure of information and 
adequate individual capacity could be assumed for the domains where subjects performed 
well (Joffe et al., 2001). Further, the QuIC could potentially act as a screen for adequacy of 
both disclosure and capacity, with lower domain scores indicating problem areas for 
understanding. Understanding the origin of participants’ misunderstanding of the key 
elements of consent and assent may illuminate areas for future intervention-based research 
focused on improving the overall quality of ICD/IADs. Future studies may include the use 
of the QuIC shortly after the cancer clinical trial ICD/IAD followed by in depth qualitative 
interviews aimed at exploring the origin of the participants’ misunderstandings of informed 
consent and assent.
While this study may have uncovered rich descriptions of the consent and assent process 
from the perspective of the participants, much work is needed to begin building a conceptual 
framework for further empirical study. Future research designs should involve audio-
recording of the actual assent process for the cancer clinical trial coupled with qualitative 
retrospective interviews after the assent process so that participant perspectives can be 
compared and integrated with actual content analysis of the ICD/IAD.
Implications for Practice
Findings from this study indicate that this sample of adolescents and their mothers generally 
felt positively about the physician providers that facilitated the consent and assent 
discussion. When adolescents and their mothers had a positive impression of their physician 
providers and their physician providers’ communication style, participants had an overall 
positive impression of the consent and assent experience. Exploring this notion of 
connectedness with physician providers as a measure of overall satisfaction in the ICD/IAD 
for pediatric oncology research can provide focus for the physician provider’s approach to 
these discussions.
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Additionally, adolescent participants in this study demonstrated a need to hear certain 
elements of the consent and assent discussion in language they could understand. The high 
level of interaction and engagement on the part of the adolescents in their descriptions of the 
consent and assent experience illuminates the necessity of involving adolescents in the 
discussion in a meaningful way that takes into account the wide variation in their 
developmental level and level of maturity. Providers must be cognizant of the necessity to 
meet the adolescent where they are and must spend time identifying the specific 
informational needs of each adolescent and their families.
Final Thoughts
As the number of pediatric clinical research participants continues to rise, researchers are 
obligated to elevate the science and literature surrounding crucial elements of human 
subjects protection for this vulnerable population. Children and adolescents are not just 
small adults, and the study of their experience of consent and assent and involvement in 
crucial decision-making processes should be focused specifically as their unique set of 
characteristics make them different from adults. Research that honors the developing 
autonomy of children and adolescents and takes into account the wide variation in their 
development and maturation is necessary to create empirically-based guidelines for the 
operationalization of the concept of consent and assent in real time clinical research practice.
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• Despite reporting positive perceptions of their experiences in informed 
consent and assent, adolescents and their parents have poor recollection 
of essential elements of informed consent and assent.
• Rushed timelines and vast amounts of information make consent and 
assent difficult processes to facilitate.
• Adolescents and parents highlight real ‘ connections’ with their 
providers as markers for a good consent and assent process.
Poston Page 16



























Template Utilized for all Semi-Structured Qualitative Interviews for Adolescents and their Parents/Guardians
Opening Statements
Thank you for agreeing to participate in this conversation with me about your informed
consent/assent experience.
I would like you to tell me the story about how you decided to (or not to) participate in the
cancer clinical trial with Dr. X.
Questions
1 Describe what this experience was like for you. What happened on the day of this discussion’ Tell me about that 
particular day.
2 What happened during the informed consent/assent discussion? What was it like? What was The room like? Who was in 
the room?
3 Who did most of the talking? What did they say? What did you say to them?
4 What was most helpful about this experience? What was least helpful about this experience?
Notes. Derived from Interview #1, which took place within 72 Hours of the Informed Consent Discussion/Informed Assent Discussion for the 
oncology clinical trial.






















    Male 3 0
    Female 1 4
Race
    Caucasian 0 0
    African-American 4 4
Age
    12–14 years 1
    15–16 years 1
    17-<18 years 2
    25–34 years 0
    35–44 years 3
    45–54 years 1
Diagnosis
    Acute Myeloid Leukemia 1
    Hodgkin’s Lymphoma 1
    Sarcoma 2
Phase of Cancer Clinical Trial
    Phase II 0
    Phase III 4
Previous Clinical Research Experience
    None 4 3
    1x or > 0 1
Length of Assent Form for Cancer Trial
    1 Page 4
    >1Page 0
Length of Consent Form for Cancer Trial
    10–19 pages 1
    20–29 pages 2
    30–39 pages 1















Clinical Research Staff Participant Demographic Characteristics
Characteristic N
Gender
    Male 2
    Female 1
Race
    Caucasian 3
    African-American 0
Age
    25–34 years 0
    35–44 years 3
    45–54 years 0
Role of Clinical Research Staff
    Physician/Principal Investigator 3
Years of Clinical Research Experience
    0–5 1
    6–10 1
    11–20 1
Years of Pediatric Clinical Experience
    0–5 1
    11–20 2
Continuing Education Completed in Last 1–3 years
    CITI Training 3
    Focused Training on Ethical Conduct in Clinical Research 1
    Focused Training on Informed Consent/Assent in Clinical Research 1
    Focused Training on Pediatric/Adolescent Participation in Clinical Research 0
    Other Continuing Education Activity 1
Continuing Education Experiences over the Lifetime
    CITI Training 3
    Focused Training on Ethical Conduct in Clinical Research 3
    Focused Training on Informed Consent/Assent in Clinical Research 3
    Focused Training on Pediatric/Adolescent Participation in Clinical 1
Research
    Other Continuing Education Activity 1















QuIC Summary Scores for Adolescent and Parent Participants
Characteristic Participants
Adolescent 1 Adolescent 2 Adolescent 3 Adolescent 4
Race AA AA AA AA
Sex F M M M
QuIC Score (Part A) 72/100 66/100 53/100 66/100
QuIC Score (Part B) 82/100 86/100 60/100 89/100
Parent 1 Parent 2 Parent 3 Parent 4
Race AA AA AA AA
Sex F F F F
QuIC Score (Part A) 47/100 70/100 52/100 67/100
QuIC Score (Part B) 86/100 100/100 100/100 86/100
Note. AA = African American; F = female; M = male; QuIC Score (Part A) > Objective Understanding Summary Score; QuIC Score (Part B) > 
Subjective Understanding Summary Score















Themes and Key Illustrative Quotes





desire to give back
as a motive for
participating in a
clinical trial.
Dr. XX told us
about it and I was
like, yeah, sure,
why not. Because if
it helps someone
else and especially






Yeah, we’re big givers and
we like to give something
back and my son like I said,
he cares so much about
other people, sometimes he
forgets himself.
… So that the next time
somebody, a child comes in
in her situation or similar
you know, using her
stuff… contributing what
they doing to her to the next
person so that they’ll know
how to help the next person.
And then just
basically told them







was in the study or




















did most of the
talking. I was a
little bit confused
so I just sat and





…a big word that
described one of
the medicines, as
soon as he said
that, that lost me
right there.
…He used that, he
used a giant word





big words? He said
he has to learn all




It wasn’t real, you hear
about this, you know people
that go through this but you
never think that it’s going to
happen to you and then
when it’s your child and you
have no control over it, it’s
like, it is overwhelming and
it’s hard.
It was just all of the
paperwork that I had there
signing over the last week or
so… It was just
overwhelming anyway
having to read something
else long again.








are so many issues





about, drugs and all
of their toxicities and
the concepts of
clinical trials, the




life for a year, it’s a
lot for a family to
absorb and so I
always feel, and this










and lack of ability









want any more bad
news.
Now there is a thin line
between sane and insane,
and I really, really, really
realized that when I found
out that my son had cancer,
because I was, I was on the
verge of just like a mental
breakdown. … [W]hen stuff
is out of my control I just
don’t know what to do. I
panic, I don’t know what to
do when it’s out of my
control and you want to do
everything you can to make
it right because that’s what







I liked the fact that
he didn’t jump
First of all he kept making
eye contact with my son,
So I was sitting on a
stool. The patient
























and he told me
straight forward
The way she just
tells it like it is
Like she shows
that she cares and
that she is trying
her best to help.
with myself and with his
dad. So he made each one of
us feel that we were part of
the conversation, which is
very important.
She is a very very to the
point type person.
Most people in situations
like that they care more
about the research than the
patient…She was totally into
X and getting her straight
and squared away.
He also did not talk to us in
so many medical terms. You
know he did say the
medical…information. You
know names and treatments
and types and different
things. But then he gave it to
us in layman terms, which
was really good.
was on the exam
table. Mom was
sitting in one of the
chairs and the nurse
was sitting in the
other chair. So we
were all seated and
the patient was
higher than eye level
so at least we were
able to sit and all be
face to face
essentially in a tiny
little circle.
I think the hard part




they don’t get it, for
a lot of families I
don’t think they read
the consent forms
because they are so
overwhelming. So
for me I try to really
sum up in layman
terms as possible
what the study is
about…trying to use
examples that would
make sense in the
day to day rather


















I wish everything, I
wish everything
would slow down.
It does go fast and
some things I
would like to slow
down…It seems
like everything was
moving so fast, I
don’t really have
time to really think
about it all that
much.
You need to take time
especially in these situations
with juveniles…Because I
mean you have to consider
that you know I just thought
that he had this upper
respiratory thing, bronchitis
you know, a bad cold. And
in an hour and a half my life
change, his life changed…I
mean our lives completely
changed the moment that
doctor said leukemia.
It’s hard because it
always feels so
rushed in having to
talk about so many
things.
That day was chaotic
from the outside of
that room. …because
I was on hospital
service and there
were other things
going on so I was
bouncing around…I
think in, you know,
the ideal world I
would have liked to
have had a little bit
more face time with















She called us in
that day to tell us
about what she’s
going to be doing
and what type of
medicine I’ll be
taking and stuff.
And how often I
take it and how,
how many days of
that week will I be
in the hospital and
how long I’ll take
chemo and
radiation. And she
You can see the little road
map that was there. Because
if you did okay, if you did
okay with the first one, if it
lessened, then it would be
either minimum or no
radiation.
There is actually
kind of a schema of
how you decide
where kids go.














Theme & Definition Key Quotes by Participant Role
Adolescent Parent Provider




until it can shrink





















I didn’t talk much









said to make sure.
So I just basically, I mean, I
think I understood at the
time but once she left out the
room… I really didn’t
remember what we talked
about. Like honestly and
that was scaring me too, like
I just had a whole
conversation about my baby
with this lady and honestly I
don’t remember what it was
about.
I really don’t remember. I
was honestly going through
so much, so I hardly
remember actually the
conversation, honestly.
I can’t remember. She says
she gets 12 bouts of chemo
or then she starts radiation
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